Esophageal pharmacology and treatment of primary motility disorders

Diseases of the Esophagus

Volumn 12, Issue 4, 1999, Pages 241-257

  Storr, M ^a   Allescher, H D ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; NITRIC ACID DERIVATIVE;

BALLOON DILATATION; ESOPHAGUS ACHALASIA; ESOPHAGUS FUNCTION DISORDER; ESOPHAGUS MOTILITY; ESOPHAGUS MUSCLE; HUMAN; LOWER ESOPHAGUS SPHINCTER PRESSURE; MANOMETRY; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE CONTRACTION; SWALLOWING;

ANIMALS; BEHAVIOR THERAPY; BOTULINUM TOXINS; CHOLINERGIC AGENTS; CLINICAL TRIALS; ESOPHAGEAL ACHALASIA; ESOPHAGEAL MOTILITY DISORDERS; ESOPHAGUS; ETHANOL; HUMANS; NARCOTICS; PROGNOSIS; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME;

EID: 0033511796     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2050.1999.00059.x     Document Type: Review

References (133)

1. Katz P O, Dalton C B, Richter J E, Wu W C, Castell D O. Esophageal testing of patients with noncardiac chest pain or dysphagia. Results of three years' experience with 1161 patients. Ann Intern Med 1987; 106: 593-597.
2. Adamek R J, Wegener M, Wienbeck M, Pulte T. Esophageal motility disorders and their coexistence with pathologic acid reflux in patients with noncardiac chest pain. Scand J Gastroenterol 1995; 30: 833-838.
3. Achem S R, Kolts B E, Wears R, Burton L, Richter J E . Chest pain associated with nutcracker esophagus: a preliminary study of the role of gastroesophageal reflux [see comments]. Am J Gastroenterol 1993; 88: 187-192.
4. Anand N, Paterson W G. Role of nitric oxide in esophageal peristalsis. Am J Physiol 1994; 266: G123-G131.
5. Allescher H D, Ravich W J. Medical treatment of esophageal motility disorders. Dysphagia 1993; 8: 125-134.
6. Korda P, Barnert J, Schmidbaur W, Wienbeck M. Effect of molsidomine on esophageal motility in patients with non-cardiac thoracic pain. Med Klin 1994; 89(suppl. 2): 73-74.
7. Farrell R L, Roling G T, Castell D O. Stimulation of the incompetent lower esophageal sphincter. A possible advance in therapy of heartburn. Am J Dig Dis 1973; 18: 646-650.
8. McCallum R W, Kline M M, Curry N. Comparative effects of metoclopramide and bethanechol on LESP in reflux patients. Gastroenterology 1975; 68: 1114-1118.
9. Farrell R L, Roling G T, Castell D O. Cholinergic therapy of chronic heartburn. A controlled trial. Ann Intern Med 1974; 80: 573-576.
10. Paterson W G, Selucky M, Hynna L T. Effect of intraesophageal location and muscarinic blockade on balloon distension-induced chest pain. Dig Dis Sci 1991; 36: 282-288.
11. Blackwell J N, Dalton C B, Castell D O. Oral pirenzepine does not affect esophageal pressures in man. Dig Dis Sci 1986; 31: 230-235.
12. Erckenbrecht E, Berges W, Sonnenberg A, Erckenbrecht J, Wienbeck M. The effect of pirenzepine on esophageal motility. Scand J Gastroenterol 1982; 72: 185-190.
13. Hassan M, Dalton C B, Castell J A, Castell D O. Pirenzepine and propantheline effects on esophageal pressure responses to bethanechol. Am J Gastroenterol 1986; 81: 334-338.
14. Kongo M, Traube M, McCallum R W. Comparison of effects of nifedipine, propantheline bromide, and the combination on esophageal motor function in normal volunteers. Dig Dis Sci 1984; 29: 300-304.
15. Marzio L, Pieramico O, Neri M. et al. Comparative study of the effects of cimetropium bromide and atropine on human esophageal motor functions. Digestion 1989; 44: 117-123.
16. Bassotti G, Gaburri M, Imbimbo B P. et al. Manometric evaluation of cimetropium bromide activity in patients with the nutcracker oesophagus. Scand J Gastroenterol 1988; 23: 1079-1084.
17. Marzio L, Grossi L, DeLaurentiis M F, Cennamo L, Lapenna D, Cuccurullo F. Effect of cimetropium bromide on esophageal motility and transit in patients affected by primary achalasia. Dig Dis Sci 1994; 39: 1389-1394.
18. Tokuhara T, Meulemans A, De Ridder W, Higashino M, Kinoshita H, Schuurkes J. Effect of adrenoceptor agonists on striated muscle strips of the canine oesophagus. Br J Pharmacol 1993; 297-302.
19. DiMarino-AJ J, Cohen S. Effect of an oral beta2-adrenergic agonist on lower esophageal sphincter pressure in normals and in patients with achalasia. Dig Dis Sci 1982; 27: 1063-1062.
20. Lyrenas E, Abrahamsson H. Beta-adrenergic influence on oesophageal peristalsis in man. Gut 1986; 27: 260-266.
21. Lyrenas E, Sand C, Abrahamsson H. Inhibitory effects of terbutaline on human esophageal peristalsis and development of tolerance. Scand J Gastroenterol 1993; 28: 907-910.
22. Weihrauch T R, Waldeck F, Forster C F, Ewe K. The effect of fenoterol on the tonus of the esophageal sphincter in achalasia. Verh Dtsch Ges Inn Med 1978; 84: 979-982.
23. Hogan W J, Viegas-de A S, Winship D H. Ethanol-induced acute esophageal motor dysfunction. J Appl Physiol 1972; 32: 755-760.
24. Mayer E M, Grabowski C J, Fisher R S. Effects of graded doses of alcohol upon esophageal motor function. Gastroenterology 1978; 75: 1133-1136.
25. Nazer H, Wright R A. The effect of alcohol on the human alimentary tract: a review. J Clin Gastroenterol 1983; 5: 361-365.
26. Grande L, Manterola C, Ros E, Lacima G, Pera C. Effects of red wine on 24-hour esophageal pH and pressures in healthy volunteers. Dig Dis Sci 1997; 42: 1189-1193.
27. Grande L, Monteforte R, Ros E, Toledo V, Estruch R, Lacima G, Urbano A, Pera C. Hyperperistalsis in the middle third of the esophagus: A manometric marker of chronic alcoholism? Gut 1996; 38: 662.
28. Keshavarzian A, Polepalle C, Iber F, Dushi M. Esophageal motility disorders in alcoholics: result of alcoholism or withdrawl? Alcohol Clin Exp Res 1996; 14: 561-567.
29. Fields J Z, Jacyno M, Wasyliw R, Winship D, Keshavarzian A. Ethanol inhibits contractility of esophageal smooth muscle strips. Alcohol Clin Exp Res 1995; 19: 1403-1413.
30. Keshavarzian A, Gordon J H, Willson C, Urban G, Fields J Z. Chronic ethanol feeding produces a muscarinic receptor upregulation but not a muscarinic supersensitivity in lower esophageal sphincter muscle. J Pharmacol Exp Ther 1992; 260: 601-607.
31. Dodds W. J, Stewart E T, Kishk S M, Kahrilas P J, Hogan W J. Radiologic amyl nitrite test for distinguishing pseudoachalasia from idiopathic achalasia. Am J Roentgenol 1986; 146: 21-23.
32. Preiksaitis H, Tremblay L, Diamant N. Nitric oxide mediates inhibitory nerve effects in human esophagus and lower esophageal sphincter. Dig Dis Sci 1994; 39: 770-775.
33. Conklin J. NO: A mediator of esophageal motor function. J Lab Clin Med 1998; 10-20.
34. Tottrup A, Svane D, Forman A. Nitric oxide mediating NANC inhibition in opossum lower esophageal sphincter. Am J Physiol 1991; 260: G385-G389.
35. Paterson W G, Anderson M, Anand N. Pharmacological characterisation of lower esophageal sphincter relaxation induced by swallowing, vagal efferent nerve stimulation and esophageal distetion. Can J Phsiol Pharmacol 1992; 70: 1011-1015.
36. Yamato S, Spechler S, Goyal R K. Role of nitric oxide in esophageal peristalsis in the opossum. Gastroenterology 1992; 103: 197-204.
37. Murray J, Ledlow A, Launspach J, Evans D, Loveday M, Conklin J. The effects of recombinant human hemoglobin on esophageal motor function in human. Gastroenterology 1995; 1241-1248.
38. Gelfond M, Rozen P, Gilat T. Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation. Gastroenterology 1982; 83: 963-969.
39. Orlando R C, Bozymski E M. Clinical and manometric effects of nitroglycerin in diffuse esophageal spasm. N Engl J Med 1973; 289: 23-25.
40. Kikendall J W, Mellow M H. Effect of sublingual nitroglycerin and long-acting nitrate preparations on esophageal motility. Gastroenterology 1980; 79: 703-706.
41. Mellow M H. Effect of isosorbide and hydralazine in painful primary esophageal motility disorders. Gastroenterology 1982; 83: 364-370.
42. Bortolotti, M., Coccia G, Brunelli F. et al. Isosorbide dinitrate or nifedipine: which is preferable in the medical therapy of achalasia? Ital J Gastroenterol 1994; 26: 379-382.
43. Allescher H D, Willis S, Stoschus B, Schusdziarra V, Classen M. Effect of molsidomine on esophageal motility in man. Med Klin 1994; 89: 71-72.
44. Willis S, Allescher H D, Stoschus B, Schusdziarra V, Classen M, Schumpelick V. Double blind placebo controlled study on the effect of the nitric oxide donor molsidomin and the 5-HT3 antagonist ondansetron on human esophageal motility. Z Gastroenterol 1994; 32: 632-636.
45. Bortolotti M, Brunelli F, Sarti P, Miglioli M. Clinical and manometric effects of L-arginine in patients with chest pain and oesophageal motor disorders. Ital J Gastroenterol Hepatol 1997; 29: 320-324.
46. Konturek J, Gillessen A, Domschke W. Diffuse esophageal spasm, a malfunction that involves nitric oxide? Scand J Gastroenterol 1995; 1041-1045.
47. Luiking Y, Weusten B, Portincasa P, Van Der Meer R, Smout A, Akkermans L. Effects of long-term oral L-arginin on esophageal motility and gallbladder dynamics in healthy humans. Am J Physiol 1998; 274: G984-G991.
48. Cattau-El J, Castell D O, Johnson D A. et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol 1991; 86: 272-276.
49. Konrad D I, Baunack A R, Ramsch K D. et al. Effect of the calcium antagonists nifedipine, nitrendipine, nimodipine and nisoldipine on oesophageal motility in man. Eur J Clin Pharmacol 1991; 41: 313-316.
50. Nasrallah S M. Nifedipine in the treatment of diffuse oesophageal spasm. Lancet 1982; 2: 1285.
51. Richter J E, Spurling T J, Cordova C M, Castell D O. Effects of oral calcium blocker diltiazem, on esophageal contractions. Studies in volunteers and patients with nutcracker esophagus. Dig Dis Sci 1984; 29: 649-656.
52. Traube M, Dubovik S, Lange R C, McCallum R W. The role of nifedipine therapy in achalasia: results of a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 1989; 84: 1259-1262.
53. Weiser H F, Lepsien G, Golenhofen K, Schattenmann G, Siewert R. Clinical and experimental studies on the efficiency of nifedipine on smooth muscle strips of the esophagus. Z Gastroenterol 1977; 15: 691-698.
54. Becker B S, Burakoff R. The effect of verapamil on the lower esophageal sphincter pressure in normal subjects and in achalasia. Am J Gastroenterol 1983; 78: 773-775.
55. Malagelada J R, Distrutti E. Management of gastrointestinal motility disorders. A practical guide to drug selection and appropriate ancillary measures. Drugs 1996; 52: 494-506.
56. Albibi R, McCallum R W. Metoclopramide: pharmacology and clinical application. Ann Intern Med 1983; 98: 86-95.
57. Schulze D K. Metoclopramide. Gastroenterology 1979; 77: 768-779.
58. Champion M C. Domperidone. Gen Pharmacol 1988; 19: 499-505.
59. Weihrauch T R, Forster C F, Krieglstein J. Evaluation of the effect of domperidone on human oesophageal and gastroduodenal motility by intraluminal manometry. Postgrad Med J 1979; 55(suppl. 1): 7-10.
60. Koelz H R. Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs. An analysis of randomized clinical trials. Scand J Gastroenterol 1989; 156 (suppl.): 25-36.
61. Clarke D E, Craig D A, Fozard J R. The 5-HT4 receptor: naughty, but nice. Trends Pharmacol Sci 1989; 10: 385-386.
62. Gilbert R J, Dodds W J, Kahrilas P J, Hogan W J, Lipman S. Effect of cisapride, a new prokinetic agent, on esophageal motor function. Dig Dis Sci 1987; 32: 1331-1336.
63. Wallin L, Kruse A S, Madsen T, Boesby S. Effect of cisapride on the gastro-oesophageal function in normal human subjects. Digestion 1987; 37: 160-165.
64. Corazziari E, Bontempo I, Anzini F. Effects of cisapride on distal esophageal motility in humans. Dig Dis Sci 1989; 34: 1600-1605.
65. Robertson C S, Evans D F, Ledingham S J, Atkinson M. Cisapride in the treatment of gastro-oesophageal reflux disease. Alimentary Pharmacol Ther 1993; 7: 181-190.
66. Janisch H D, Huttemann W, Bouzo M H. Cisapride versus ranitidine in the treatment of reflux esophagitis. Hepatogastroenterology 1988; 35: 125-127.
67. Horowitz M, Maddox A, Wishart J, Corazziari E. The effect of cisapride on gastric and esophageal emptying in 10 patients with dystrophia myotonica. J Gastroenterol Hepatol 1987; 285-293.
68. Horowitz M, Maddern G J, Maddox A, Wishart J, Chatterton B E, Shearman D J. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology 1987; 93: 311-315.
69. Kahan A, Chaussade S, Gaudric M. et al. The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study. Br J Clin Pharmacol 1991; 31: 683-687.
70. Cucchiara S, Santamaria F, Andreotti M. et al. Mechanisms of gastroesophageal reflux in cystic fibrosis. Arch Dis Child 1991; 617-622.
71. Horowitz M, Maddox A, Harding P E. et al. Effect of cisapride on gastric and esophageal emptying in insulin-dependent diabetes mellitus. Gastroenterology 1987; 92: 1899-1907.
72. Song C W, UM S H, Kim C D,. Ryu H S, Hyun J H, Choe J G. Double-blind placebo-controlled study of cisapride in patients with nonspecific esophageal motility disorder accompanied by delayed esophageal transit. Scand J Gastroenterol 1997; 32: 541-546.
73. Wienbeck M, Li Q. Cisapride in gastro-oesophageal reflux disease: effects on oesophageal motility and intra-oesophageal pH. Scand J Gastroenterol 1989; 165(suppl.): 13-18.
74. Mine Y, Yoshikawa T, Oku S, Nagai R, Yoshida N, Hosoki K. Comparison of effect of mosapride citrate and existing 5HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. J Pharmacol Exp Ther 1997; 283: 1000-1008.
75. Yoshida N, Omoya H, Kato S, Ito T. Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Arzneim Forsch Drug Res 1993; 43: 1078-1083.
76. Yoshida N, Kato S, Ito T. Mosapride citrate. Drugs Future 1993; 18: 513-515.
77. Cohen M, Bloomquist W, Schaus J, Thompson T, Susemichel A. LY35344, a potent, orally effective, long acting 5HT4 receptor antagonist: comparison to cisapride and RS23597-190. J Pharmacol Exp Ther 1996; 277: 97-104.
78. Tzovaras G, Xynos E, Chrysos E, Mantides A, Vassilakis J S. The effect of intravenous erythromycin on esophageal motility in healthy subjects. Am J Surg 1996; 171: 316-319.
79. Pehl C, Pfeiffer A, Wendl B, Stellwag B, Kaess H. Effect of erythromycin on postprandial gastroesophageal reflux in reflux esophagitis. Dis Esoph 1997; 10: 34-37.
80. Pennathur A, Tran A, Cioppi M, Fayad J, Sieren G L, Little A G. Erythromycin strengthens the defective lower esophageal sphincter in patients with gastroesophageal reflux disease. Am J Surg 1994; 167: 169-172.
81. Champion G, Richter J E, Singh S, Schan C, Nellans H. Effects of oral erythromycin on esophageal pH and pressure profiles in patients with gastroesophageal reflux disease. Dig Dis Sci 1994; 39: 129-137.
82. Kao C H, Wang S J, Pang D Y. Effects of oral erythromycin on upper gastrointestinal motility in patients with noninsulin-dependent diabetes mellitus. Nucl Med Commun 1995; 16: 790-793.
83. Tsai S C, Kao C H, Pan D Y, ChangLai S P, Wang S J. Effects of oral erythromycin on esophageal motility in patients with noninsulin-dependent diabetes mellitus. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1995; 11: 430-435.
84. Greenwood B, Dieckman D, Kirst H A, Gidda J S. Effects of LY267108, an erythromycin analogue derivative, on lower esophageal sphincter function in the cat. Gastroenterology 1994; 106: 624-628.
85. Penagini R, Bianchi P A. Effect of morphine on gestroesophageal reflux and transient lower esophageal sphincter relaxation. Gastroenterology 1997; 113: 409-414.
86. Penagini R, Picone A, Bianchi P A. Effect of morphine and naloxone on motor response of the human esophagus to swallowing and distension. Am J Physiol 1996; 271: G675-G680.
87. Penagini, Bartesaghi B, Negri G, Bianchi P A. Effect of loperamide on lower oesophageal sphincter pressure in idiopathic achalasia. Scand J Gastroenterol 1994; 29: 1057-1060.
88. Bhutani M S. Gastrointestinal uses of botulinum toxin. Am J Gastroenterol 1997; 92: 929-933.
89. Allescher H D. Einsatz von Botulinum Toxin in der Gastroenterologie. Münch Med Wschr 1998; 140: 486-489.
90. Annese V, Basciani M, Perri F. et al. Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia. Gastroenterology 1996; 111: 1418-1424.
91. Pasricha P J, Ravich W J, Hendrix T R, Sostre S, Jones B, Kalloo A N. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995; 332: 774-778.
92. Pasricha P J, Ravich W J, Kalloo A N. Botulinum toxin for achalasia. Lancet 1993; 341: 244-245.
93. Allescher H D, Seige M, Gonzales R. et al. Botulinumtoxin Injektion versus pneumatische Ballondilatation in der Behandlung der Achalasie. Z Gastroenterol 1998; 36: 684.
94. Jones M P. Botulinum toxin in hypertensive lower esophageal sphincter [letter]. Am J Gastroenterol 1996; 91: 1283-1284.
95. Clouse R E, Lustman P J. Psychiatric illness and contraction abnormalities of the esophagus. N Engl J Med 1983; 309: 1337-1342.
96. Anderson K O, Dalton C B, Bradley L A, Richter J E. Stress induces alteration of esophageal pressures in healthy volunteers and non-cardiac chest pain patients. Dig Dis Sci 1989; 34: 83-91.
97. Cooc I, Dent J, Shannon S, Collins S. Measurement of upper esophageal sphincter pressure: effect of acute emotional stress. Gastroenterology 1987; 526-532.
98. Richter J E, Obrecht W F, Bradley L A, Young L D, Anderson K O. Psychological comparison of patients with nutcracker esophagus and irritable bowel syndrome. Dig Dis Sci 1986; 31: 131-138.
99. Clouse R E, Lustman P J, Eckert T C, Ferney D M, Griffith L S. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 1987; 92: 1027-1036.
100. Cannon R O, Quyyumi A A, Mincemoyer R. et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994; 330: 1411-1417.
101. Peghini P L, Katz P O, Castell D O. Imipramine decreases oesophageal pain perception in human male volunteers. Gut 1998; 42: 807-813.
102. Gorelick A B, Koshy S S, Hooper F G, Bennett T C, Chey W D, Hasler W L. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998; 275: G460-G466.
103. Weihrauch T R, Forster C F, Kohler H, Ewe K, Krieglstein J. Effect of intravenous diazepam on human lower oesophageal sphincter pressure under controlled double blind crossover conditions. Gut 1979; 20: 64-67.
104. Reveille R M, Goff J S, Hollstrom T K. The effect of intravenous diazepam on esophageal motility in normal subjects. Dig Dis Sci 1991; 36: 1046-1049.
105. Beitman B D, Basha I M, Trombka L H. et al. Alprazolam in the treatment of cardiology patients with atypical chest pain and panic disorder. J Clin Psychopharmacol 1988; 8: 127-130.
106. Latimer P R. Biofeedback and self-regulation in the treatment of diffuse esophageal spasm: a single-case study. Biofeedback Self Regul 1981; 6: 181-189.
107. Mittal R, Shaffer H, Parollisi S, Baggett L. Influence of breathing pattern on the esophagogastric junction pressure and esophageal transit. Am J Physiol 1995; 269: G577-G583.
108. Valori R, Hallisey M, Dunn J. Power of esophageal peristalsis can be controlled voluntarily. Gut 1991; 32: 236-239.
109. Guelrud M, Rossiter A, Souney P F, Sulbaran M. Transcutaneous electrical nerve stimulation decreases lower esophageal sphincter pressure in patients with achalasia. Dig Dis Sci 1991; 36: 1029-1033.
110. Kaada B. Successful treatment of esophageal dysmotility and Raynaud's phenomenon in systemic sclerosis and achalasia by transcutaneous nerve stimulation. Increase in plasma VIP concentration. Scand J Gastroenterol 1987; 22: 1137-1146.
111. Borjesson M, Pilhall M, Eliasson T, Norssell H, Mannheimer C, Rolny P. Esophageal visceral pain sensitivity: effects of TENS and correlation with manometric findings. Dig Dis Sci 1998; 43: 1621-1628.
112. Scheiman J, Patel P, Henson E, Nostrant T. Effect of naproxen on gastroesophageal reflux and esophageal function: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 1995; 90: 754-757.
113. Sandler A, Maher J W, Weinstock J. et al. Tachykinins in the canine gastroesophageal junction. Am J Surg 1991; 165-170.
114. Uc A, Murray J, Conklin J. Effects of calcitonin gene-related peptide on opossum esophageal smooth muscle. Gastroenterology 1997; 113: 514-520.
115. Holloway R, Lyrenas E, Ireland A, Dent J. Effect of intraduodenal fat on lower esophageal sphincter function and gastroesophageal reflux. Gut 1997; 40: 449-453.
116. Murthy K S, Grider J R, Jin J G, Makhlouf G M. Interplay of VIP and nitric oxide in the regulation of neuromuscular activity in gut. Arch Int Pharmacodyn Ther 1995; 329: 27-38.
117. Blackwell J N, Holt S, Heading R C. Effect of nifedipine on oesophageal motility and gastric emptying. Digestion 1981; 21: 50-56.
118. Bortolotti M, Labo G. Clinical and manometric effects of nifedipine in patients with esophageal achalasia. Gastroenterology 1981; 80: 39-44.
119. Coccia G, Bortolotti M, Michetti P, Dodero M. Return of esophageal peristalsis after nifedipine therapy in patients with idiopathic esophageal achalasia. Am J Gastroenterol 1992; 87: 1705-1708.
120. Triadafilopoulos G, Aaronson M, Sackel S, Burakoff R. Medical treatment of esophageal achalasia. Double-blind crossover study with oral nifedipine, verapamil, and placebo [see comments]. Dig Dis Sci 1991; 36: 260-267.
121. Annese V, D'Onofrio V, Andriulli A. Botulinum toxin in long-term therapy for achalasia. Ann Intern Med 1998; 128: 696.
122. Pasricha P J, Ravich W J, Hendrix T R, Sostre S, Jones B, Kalloo A N. Treatment of achalasia with intrasphincteric injection of botulinum toxin. A pilot trial. Ann Intern Med 1994; 121: 590-591.
123. Pasricha P J, Rai R, Ravich W J, Hendrix T R, Kalloo A N. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology 1996; 110: 1410-1415.
124. Moreto M, Ojembarrena E, Rodriguez M L. Endoscopic injection of ethanolamine as a treatment for achalasia: a first report. Endoscopy 1996; 28: 539-545.
125. Triadafilopoulos G, Tsang H P. Olfactory stimuli provoke diffuse esophageal spasm: reversal by ipratropium bromide. Am J Gastroenterol 1996; 91: 2224-2227.
126. Miller L S, Parkman H P, Schiano T D. et al. Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Dig Dis Sci 1996; 41: 2025-2031.
127. Davies H A, Lewis M J, Rhodes J, Henderson A H. Trial of nifedipine for prevention of oesophageal spasm. Digestion 1987; 36: 81-83.
128. Drenth J P, Bos L P, Engels L G. Efficacy of diltiazem in the treatment of diffuse oesophageal spasm. Alimentary Pharmacol Ther 1990; 4: 411-416.
129. Richter J E, Dalton C B, Bradley L A, Castell D O. Oral nifedipine in the treatment of noncardiac chest pain in patients with the nutcracker esophagus. Gastroenterology 1987; 93: 21-28.
130. Triadafilopoulos G, Tsang H P, Segall G M. Hot water swallows improve symptoms and accelerate esophageal clearance in esophageal motility disorders. J Clin Gastroenterol 1998; 26: 239-244.
131. Winters C, Artnak E J, Benjamin S B, Castell D O. Esophageal bougienage in symptomatic patients with the nutcracker esophagus. A primary esophageal motility disorder. JAMA 1984; 252: 363-366.
132. Achem S R, Kolts B E. Current medical therapy for esophageal motility disorders. Am J Med 1992; 92: 98S-105S.
133. Leite L, Johnston B, Barrett J, Castell J, Castell D O. Ineffective esophageal motility (IME): the primary finding in patients with nonspecific esophageal motility disorder. Dig Dis Sci 1997; 42: 1859-1865.